International urology and nephrology · 2026
The importance of targeted plus perilesional prostate biopsy in prostate cancer management (diagnosis and treatment)-real world evidence of a tertiary centre.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bastos Samuel Silva, Oliveira Vítor, Dias Jorge, Xambre Luís, Sabença Ana, Maciel Rui, Lourenço Miguel, Peralta João
Аннотация
PURPOSE: To evaluate whether systematic contralateral biopsy can be safely omitted in men with MRI-detected prostate lesions (PI-RADS ≥ 3) and to assess the impact of contralateral findings on treatment decisions.
MATERIALS AND METHODS: A retrospective cohort of 617 patients with pre-biopsy multiparametric MRI showing at least one PI-RADS ≥ 3 lesion underwent cognitive MRI-targeted biopsy of the index lesion, perilesional sampling (≥ 6 cores), and contralateral systematic biopsy (≥ 6 cores). Primary endpoint was upgrading in the contralateral lobe versus index/perilesional regions. Secondary endpoint was the impact of contralateral biopsy omission on treatment decision. Statistical analyses included Friedman's test, Wilcoxon signed-rank, one-way ANOVA with Games-Howell, and McNemar's test.
RESULTS: Median age was 69 years, median PSA 7.83 ng/mL, and median prostate volume 46 cc. Positive cores were observed in 76.3%, 83.3%, and 51.9% of index, perilesional, and contralateral biopsies, respectively. Contralateral lobe ISUP grade was significantly lower than the maximum index/perilesional grade (median 1 vs 2, p < 0.001). Clinically significant prostate cancer (ISUP ≥ 2) was present in 81% of index/perilesional regions versus 39% of contralateral. Only 2.1% of patients had clinically significant cancer isolated to the contralateral lobe (number needed to test = 48). Contralateral findings altered management in 6.3% of cases, predominantly in patients with low-risk features.
CONCLUSIONS: Tumor burden is predominantly localized to the index and perilesional regions. Contralateral biopsy minimally contributes to detecting high-grade disease or modifying treatment decisions. A selective MRI-directed approach combining targeted and perilesional sampling with judicious contralateral biopsy may optimize diagnostic yield while reducing procedural burden.
MATERIALS AND METHODS: A retrospective cohort of 617 patients with pre-biopsy multiparametric MRI showing at least one PI-RADS ≥ 3 lesion underwent cognitive MRI-targeted biopsy of the index lesion, perilesional sampling (≥ 6 cores), and contralateral systematic biopsy (≥ 6 cores). Primary endpoint was upgrading in the contralateral lobe versus index/perilesional regions. Secondary endpoint was the impact of contralateral biopsy omission on treatment decision. Statistical analyses included Friedman's test, Wilcoxon signed-rank, one-way ANOVA with Games-Howell, and McNemar's test.
RESULTS: Median age was 69 years, median PSA 7.83 ng/mL, and median prostate volume 46 cc. Positive cores were observed in 76.3%, 83.3%, and 51.9% of index, perilesional, and contralateral biopsies, respectively. Contralateral lobe ISUP grade was significantly lower than the maximum index/perilesional grade (median 1 vs 2, p < 0.001). Clinically significant prostate cancer (ISUP ≥ 2) was present in 81% of index/perilesional regions versus 39% of contralateral. Only 2.1% of patients had clinically significant cancer isolated to the contralateral lobe (number needed to test = 48). Contralateral findings altered management in 6.3% of cases, predominantly in patients with low-risk features.
CONCLUSIONS: Tumor burden is predominantly localized to the index and perilesional regions. Contralateral biopsy minimally contributes to detecting high-grade disease or modifying treatment decisions. A selective MRI-directed approach combining targeted and perilesional sampling with judicious contralateral biopsy may optimize diagnostic yield while reducing procedural burden.